×
Customize
?
Start
Cancer Types
Quick Links
Events
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Myeloma
Featured Content
Dr Noopur Raje opens this program with a brief discussion on the basics of multiple myeloma. She describes what the disease is, highlights key risk factors, and explains how she helps educate her patients on their diagnosis. Cynthia Harrington discusses her role as a nurse practitioner when working with multiple myeloma patients and why a team-based approach between healthcare providers and the patient is important.
CURE Staff
On social media, CURE® recently asked its readers to share the advice they would give someone looking to help a friend or loved one with cancer. Here, we share some of their responses.
Dr. Parameswaran Hari
Dr. Parameswaran Hari discusses the importance of understanding a patient’s MRD if they are receiving the maintenance therapy Sarclisa for multiple myeloma.
Ryan McDonald
The use of a mobility aide program in a cancer unit among the Mount Sinai Health System helped 76% of patients hospitalized for their cancer either maintain or improve their mobility scores, helping to reduce excess days spent in the hospital and readmission rates.
Ryan McDonald
Patients with multiple myeloma who were obese or overweight had a trend toward slightly improved progression-free survival and overall survival outcomes compared to patients who had a normal weight, according to data from an exploratory analysis.
Ryan McDonald
A roundup of the latest news and updates for patients with multiple myeloma from CURE®.
Ryan McDonald
The manufacturer is working with the Food and Drug Administration to address any requests including changes to the protocol of the MELANI-01 trial to enhance patient safety.
Gina Columbus and Ryan McDonald
The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted in favor of the agency approving belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma who have previously received at least four therapies.
Beth Fand Incollingo
The Multiple Myeloma Research Foundation’s newly launched CureCloud is a registry designed to collect clinical and genomic information about patients. Its goals are to help researchers discover treatments for various subtypes of the disease and let patients know whether they have any of 70 genetic aberrations associated with myeloma.
Ricahrd E. Farmer
Ryan McDonald
After a median follow-up of 13.3 months, the median overall response rate across all patients who received idecabtagene vicleucel (ide-cel) was 73%, including a complete response of 33%.